French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from the European Medicines Agency (EMA) for its drug Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged one to 11 years who weigh at least 15 kg. The approval covers patients who are inadequately controlled by, intolerant to, or not candidates for conventional medicinal therapy. This indication has previously been approved in the United States and Canada.
Dupixent Becomes the First and Only Medicine for Young EoE Patients in the EU
The EMA’s approval follows an initial approval in the European Union (EU) for EoE in adults and adolescents, making Dupixent the first and only medicine indicated to treat these young patients.
Understanding Eosinophilic Esophagitis (EoE)
Eosinophilic esophagitis (EoE) is a chronic type 2 inflammatory esophagitis and the most common eosinophilic gastrointestinal disease. It can severely impact a child’s ability to eat and may also cause vomiting, abdominal pain, difficulty swallowing, decreased appetite, and challenges in thriving.- Flcube.com
